Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center‐derived B‐cell lymphomas-Reference-Cited by-同舟云学术

Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center‐derived B‐cell lymphomas

Published:2020-01-13 Issue:2 Volume:111 Page:749-759
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Tanaka Yuka¹^ORCID,Momose Shuji²³^ORCID,Tabayashi Takayuki¹,Sawada Keisuke²,Yamashita Takahisa²,Higashi Morihiro²,Sagawa Morihiko¹,Tokuhira Michihide¹^ORCID,Rosenwald Andreas³,Kizaki Masahiro¹,Tamaru Jun‐ichi²

Affiliation:

1. Department of Hematology Saitama Medical Center Saitama Medical University Kawagoe Japan

2. Department of Pathology Saitama Medical Center Saitama Medical University Kawagoe Japan

3. Institute of Pathology Comprehensive Cancer Center Mainfranken University of Würzburg Würzburg Germany

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14286

Reference30 articles.

1. Double-hit and double-expressor B-cell lymphomas: Current treatment strategies and impact of hematopoietic cell transplantation

2. The genetic landscape of mutations in Burkitt lymphoma

3. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing

4. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation;BMC Cancer;2024-04-08

2. Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation;British Journal of Haematology;2024-04-05

3. Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma;Annals of Hematology;2023-10-04

4. MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer;Frontiers in Bioscience-Landmark;2023-08-30

5. Targeting the Cell Cycle and Cyclin‐dependent Kinases;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15